CNTB vs EIKN
CNTB: Clinical-stage biopharmaceutical company developing rademikibart, an IL-4Rα-targeting monoclonal antibody to treat acute exacerbations of asthma and COPD. EIKN: A clinical-stage biopharmaceutical company utilizing a proprietary technology platform to discover and develop a pipeline of novel therapeutic candidates.
Side-by-side fundamentals
| Metric | CNTB | EIKN | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $2.19 | $9.21 | |
| Market cap as of 2026-08-08 | $138M | $499M | |
| Net margin as of 2026-08-08 | -21243.3% | n/a | |
| Operating margin as of 2026-08-08 | -21763.1% | n/a | |
| ROE as of 2026-08-08 | -122.3% | -114.8% | EIKN higher |
| ROA as of 2026-08-08 | -97.1% | -54.5% | EIKN higher |
| Debt / equity as of 2026-08-08 | 0.00 | 0.00 | Tie |
| Beta as of 2026-08-08 | -0.21 | 2.15 | |
| 1-year return as of 2026-08-06 close | +2.8% | n/a |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.